Prevention of ischemic stroke in patients with myeloproliferative neoplasms
https://doi.org/10.35754/0234-5730-2024-69-2-190-199
Abstract
Introduction. Myeloproliferative neoplasms (MPNs) are a rare but significant cause of strokes.
Aim. To describe risk factors for stroke development, as well as prevention strategies based on available literature data on patients with MPN.
Main findings. Online databases (PubMed, E-Library) were searched for studies on cerebral thrombotic complications in the setting of myeloproliferative disorders. Induction of specific cytoreductive treatment with low doses of acetylsalicylic ac id should be considered as a mandatory component of secondary prevention of noncardioembolic stroke.
About the Authors
P. I. Kuznetsova
Research Center of Neurology
Russian Federation
Russian Federation
Polina I. Kuznetsova, Cand. Sci. (Med.), researcher, neurologist, 1st neurological department
125367, Moscow
A. L. Melikyan
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Anait L. Melikyan, Dr. Sci. (Med.), head of the department of standardization and treatment methods
125167, Moscow
I. N. Subortseva
National Medical Research Center for Hematology
Russian Federation
Russian Federation
Irina N. Subortseva, Cand. Sci. (Med.), researcher, hematologist, department of standardization and treatment methods
125167, Moscow
A. A. Raskurazhev
Research Center of Neurology
Russian Federation
Russian Federation
Anton A. Raskurazhev, Cand. Sci. (Med.), researcher, neurologist, 1st neurological department
125367, Moscow
M. M. Tanashyan
Research Center of Neurology
Russian Federation
Russian Federation
Marine M. Tanashyan, Dr. Sci. (Med.), Professor, Corr. Member of the RAS, Deputy director for science, Head of the 1st neurological department
125367, Moscow
References
1. Markus H.S. The global burden of stroke. Int J Stroke. 2023; 18(6): 632–3. DOI: 10.1177/17474930231181677.
2. https://vizhub.healthdata.org/gbd-compare/
3. Barbui T., Finazzi G., Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013; 122(13): 2176–84. DOI: 10.1182/blood-2013-03-460154.
4. Rebrova O.Yu., Fedyaeva V.K. Questionnaire for assessing the risk of systematic errors in randomized comparative studies: the Russian-language version of the Newcastle-Ottawa scale. Medicinskie tekhnologii. Ocenka i vybor. 2016; 3(25): 14-9. (In Russian).
5. Page M.J., McKenzie J.E., Bossuyt P.M., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: 71. DOI: 10.1136/bmj.n71.
6. Grunwald M.R., Stein B.L., Boccia R.V., et al. Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clin Lymphoma Myeloma Leuk. 2018; 18(12): 788–95.e2. DOI: 10.1016/j.clml.2018.08.009.
7. Tefferi A., Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020; 95: 1599–613. DOI: 10.1002/ajh.26008.
8. Passamonti F., Rumi E., Pietra D., et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010 Sep; 24(9): 1574–9. DOI: 10.1038/leu.2010.148.
9. Waggoner M. Polycythemia Vera: Thinking Beyond the Hematocrit. J Adv Pract. Oncol. 2023 Jul; 14(5): 405–13. D OI: 10.6004/jadpro.2023.14.5.5.
10. Burattini M., Falsetti L., Potente E., et al. Ischemic stroke as a presenting manifestation of polycythemia vera: a narrative review. Rev Neurosci. 2021; 33(3): 303–11. D OI: 10.1515/revneuro-2021-0066.
11. Haider M., Gangat N., Lasho T., et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients. Am J Hematol. 2016; 91(4): 390–4. DOI: 10.1002/ajh.24293.
12. Carobbio A., Thiele J., Passamonti F., et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117(22): 5857–9. DOI: 10.1182/blood-2011-02-339002.
13. Latagliata R., Montanaro M., Cedrone M., et al. High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Thromb Res. 2017; 156: 168–71. DOI: 10.1016/j.thromres.2017.06.023.
14. Das S., Deb A., Pal T. Antithrombotic Management in Ischemic Stroke with Essential Thrombocythemia: Current Evidence and Dilemmas. Med Princ Pract. 2021; 30(5): 412–21. DOI: 10.1159/000516471.
15. Pascale S., Petrucci G., Dragani A., et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012; 119(119): 3595–603.
16. Dragani A., Pascale S., Recchiuti A., et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood. 2010; 115(5): 1054–61.
17. Dillinger J.G., Sideris G., Henry P., et al. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb Res. 2012; 129(129): 91–4.
18. Mital A., Prejzner W., Bieniaszewska M., et al. Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients. Pol Arch Med Wewn. 2015; 125(12): 914–20.
19. Posfai E., Marton I., Szőke A., et al. Stroke in essential thrombocythemia. J Neurol Sci. 2014 Jan 15; 336(1–2): 260–2. DOI: 10.1016/j.jns.2013.10.016.
20. De Stefano V., Carobbio A., Di Lazzaro V., et al. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer J. 2018; 8(3): 25. DOI: 10.1038/s41408-018-0048-9. PMID: 29535299; PMCID: PMC5849668.
21. Finazzi G.; low-dose aspirin in polycythemia (ECLAP). A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). Pathol Biol. 2004; 52(5): 285–8. DOI: 10.1016/j.patbio.2004.02.007.
22. Gangat N., Wolanskyj A.P., Schwager S.M., et al. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Cancer. 2009; 115: 5740–5.
23. Stefanou M.I., Richter H., Hartig F., et al. Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms. Eur J Neurol. 2019; 26(6): 903-e64. DOI: 10.1111/ene.13907.
24. Košťal M., Schwarz J., Ovesna P., et al. CZEMP–Czech Group for Ph- Myeloproliferative neoplasms. Phmyeloproliferative neoplasms and the related risk factors for stroke occurrence: Results from a registry of patients treated with Anagrelide. J Thromb Thrombolysis. 2021; 51(1): 112–9. DOI: 10.1007/s11239-020-02175-8.
25. Nahrendorf M. Myeloid cell contributions to cardiovascular health and disease. Nat Med. 2018; 24(6): 711–20. DOI: 10.1038/s41591-018-0064-0.
Review
For citations:
Kuznetsova P.I., Melikyan A.L., Subortseva I.N., Raskurazhev A.A., Tanashyan M.M. Prevention of ischemic stroke in patients with myeloproliferative neoplasms. Russian journal of hematology and transfusiology. 2024;69(2):190-199. (In Russ.) https://doi.org/10.35754/0234-5730-2024-69-2-190-199
Views:
279
Email this article 
